Veterans, members of Congress, and many others advocated for the groundbreaking PTSD treatment, but the FDA declined it saying more research is needed. By Joshua Skovlund Updated Aug 12, 2024 2:37 ...

The FDA decision, scheduled for August 11, could mark a turning point in the treatment of PTSD. Concerns and criticisms surround the integrity of clinical trials, highlighting the lack of ...

June 05, 2024 FDA advisory panel votes against MDMA for treatment of PTSD Concerns about the safety of the psychedelic drug and the way studies were conducted led to the decision.

The U.S. Food and Drug Administration announced Friday its rejection of MDMA as a treatment for PTSD. ... The FDA’s decision comes nearly eight weeks after an FDA advisory committee voted 10-1 ...

An FDA advisory panel concludes that the efficacy of brexpiprazole, when started concurrently with sertraline, has not been ...

By August 11, the FDA is expected to decide whether MDMA – the chemical found in ecstasy or molly – can be prescribed as a treatment for PTSD. In a letter addressed to FDA commissioner Robert ...

In June, the FDA's Psychopharmacologic Drugs Advisory Committeevoted 9-2 against MDMA as an effective treatment for PTSD patients, and 10-1 that the drug's benefits do not outweigh the risks.

The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's ...

The U.S. Food and Drug Administration's reviewers on Wednesday raised efficacy concerns over the use of Otsuka Pharma's drug ...